Anaveon Appoints Zanelli, Jene
Analysis based on 6 articles · First reported May 19, 2026 · Last updated May 19, 2026
The appointments of Eric Zanelli>>> and Jill Jene>>> to key executive roles at Anaveon>>> are expected to accelerate the company's clinical advancement and pipeline expansion, potentially leading to increased investor confidence and future valuation. Their combined expertise in immunology, translational medicine, corporate strategy, and business development could enhance Anaveon>>>'s ability to secure funding, forge strategic partnerships, and bring novel therapies to market, positively impacting the biotechnology sector.
Anaveon>>>, a late-stage biotechnology company, announced the appointments of Eric Zanelli>>>, Ph.D., as Chief Scientific Officer and Jill Jene>>>, Ph.D., MBA, as Chief Business Officer on May 19, 2026. These strategic additions to the C-suite are intended to leverage their deep scientific, translational, and business development expertise to accelerate Anaveon>>>'s clinical advancement and pipeline expansion, particularly in the treatment of autoimmune and inflammatory diseases. Thaminda Ramanayake>>>, CEO of Anaveon>>>, highlighted their proven track records in immunology, regulatory strategy, corporate strategy, and deal-making as complementary to the company's goals of transitioning into clinical development and strengthening its immunology-focused pipeline. Eric Zanelli>>> will lead Anaveon>>>'s scientific team and advance its lead asset ANV200, while Jill Jene>>> will focus on building strategic relationships and securing resources for success.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard